These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 27539884)

  • 1. Haptoglobin 2-2 genotype and the risk of coronary artery disease in the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications study (DCCT/EDIC).
    Orchard TJ; Backlund JC; Costacou T; Cleary P; Lopes-Virella M; Levy AP; Lachin JM;
    J Diabetes Complications; 2016; 30(8):1577-1584. PubMed ID: 27539884
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Intensive lifestyle intervention in type 2 diabetes and risk of incident coronary artery disease for the common haptoglobin phenotypes: the Look AHEAD study.
    Warren RA; Bancks MP; Carew AS; Levy AP; Sapp J; Bahnson J; Lewis CE; Rimm EB; Espeland MA; Cahill LE
    Cardiovasc Diabetol; 2024 Feb; 23(1):82. PubMed ID: 38402400
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Haptoglobin genotype: a determinant of cardiovascular complication risk in type 1 diabetes.
    Costacou T; Ferrell RE; Orchard TJ
    Diabetes; 2008 Jun; 57(6):1702-6. PubMed ID: 18332093
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Haptoglobin genotype and the rate of renal function decline in the diabetes control and complications trial/epidemiology of diabetes interventions and complications study.
    Orchard TJ; Sun W; Cleary PA; Genuth SM; Lachin JM; McGee P; Paterson AD; Raskin P; Anbinder Y; Levy AP;
    Diabetes; 2013 Sep; 62(9):3218-23. PubMed ID: 23761102
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Haptoglobin Phenotype and Intensive Glycemic Control for Coronary Artery Disease Risk Reduction in People With Type 2 Diabetes: The ADVANCE Study.
    Cahill LE; Warren RA; Carew AS; Levy AP; Sapp J; Samuel M; Selvin E; Lavallée SK; Poulter N; Marre M; Harrap S; Mancia G; Harris K; Chalmers J; Woodward M; Rimm EB
    Diabetes Care; 2024 May; 47(5):835-843. PubMed ID: 38484336
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Relationship Between Time-Varying Achieved HbA1c and Risk of Coronary Events Depends on Haptoglobin Phenotype Among White and Black ACCORD Participants.
    Cahill LE; Warren RA; Carew AS; Levy AP; Ginsberg HN; Sapp J; Lache O; Rimm EB
    Diabetes Care; 2023 Nov; 46(11):1941-1948. PubMed ID: 37639669
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Does haptoglobin genotype affect early onset of diabetic retinopathy in patients with type 2 diabetes?
    Goldenberg-Cohen N; Gabbay M; Dratviman-Storobinsky O; Reich E; Axer-Siegel R; Weinberger D; Gabbay U
    Retina; 2011 Sep; 31(8):1574-80. PubMed ID: 21555971
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Association between haptoglobin 2-2 genotype and coronary artery disease and its severity in a tunisian population.
    Moussa A; Rejeb J; Omezzine A; Rebhi L; Boumaiza I; Kacem S; Ben Rejeb N; Boughzala E; Ben Abdelaziz A; Bouslama A
    Biochem Genet; 2014 Jun; 52(5-6):269-82. PubMed ID: 24535155
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Intensive Diabetes Treatment and Cardiovascular Outcomes in Type 1 Diabetes: The DCCT/EDIC Study 30-Year Follow-up.
    Diabetes Control and Complications Trial (DCCT)/Epidemiology of Diabetes Interventions and Complications (EDIC) Study Research Group
    Diabetes Care; 2016 May; 39(5):686-93. PubMed ID: 26861924
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Relationship Between Time-Varying Achieved High-Density Lipoprotein Cholesterol and Risk of Coronary Events Depends on Haptoglobin Phenotype Within the ACCORD Lipid Study.
    Warren RA; Carew AS; Andreou P; Levy AP; Sapp J; Lache O; Ginsberg HN; Rimm EB; Herman C; Kirkland S; Cahill LE
    J Am Heart Assoc; 2023 Oct; 12(19):e030288. PubMed ID: 37776200
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact of Vitamin E supplementation on vascular function in haptoglobin genotype stratified diabetes patients (EVAS Trial): a randomised controlled trial.
    Dalan R; Goh LL; Lim CJ; Seneviratna A; Liew H; Seow CJ; Xia L; Chew DEK; Leow MKS; Boehm BO
    Nutr Diabetes; 2020 Apr; 10(1):13. PubMed ID: 32341356
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Haptoglobin polymorphism in relation to coronary plaque characteristics on radiofrequency intravascular ultrasound and near-infrared spectroscopy in patients with coronary artery disease.
    Buljubasic N; Oemrawsingh RM; Smeets MB; Cheng JM; Regar E; van Geuns RJ; Serruys PW; Boersma E; Akkerhuis KM; Kardys I; Arslan F
    Int J Cardiol; 2016 Oct; 221():682-7. PubMed ID: 27423090
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of screening for coronary artery disease using CT angiography on mortality and cardiac events in high-risk patients with diabetes: the FACTOR-64 randomized clinical trial.
    Muhlestein JB; Lappé DL; Lima JA; Rosen BD; May HT; Knight S; Bluemke DA; Towner SR; Le V; Bair TL; Vavere AL; Anderson JL
    JAMA; 2014 Dec; 312(21):2234-43. PubMed ID: 25402757
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The protean role of haptoglobin and haptoglobin genotypes on vascular complications in diabetes mellitus.
    Dalan R; Liuh Ling G
    Eur J Prev Cardiol; 2018 Sep; 25(14):1502-1519. PubMed ID: 29799294
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Haptoglobin phenotype and intensive glycemic control for coronary artery disease risk reduction in people with type two diabetes: The Veterans Affairs Diabetes Trial.
    Cahill LE; Warren RA; Bahn GD; Carew AS; Levy AP; Sapp J; Rimm EB; Reaven P
    Am J Prev Cardiol; 2024 Jun; 18():100681. PubMed ID: 38800835
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Genetic Risk Factors for CVD in Type 1 Diabetes: The DCCT/EDIC Study.
    Bebu I; Keshavarzi S; Gao X; Braffett BH; Canty AJ; Herman WH; Orchard TJ; Dagogo-Jack S; Nathan DM; Lachin JM; Paterson AD;
    Diabetes Care; 2021 Jun; 44(6):1309-1316. PubMed ID: 33883194
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Haptoglobin Phenotype Modifies the Influence of Intensive Glycemic Control on Cardiovascular Outcomes.
    Carew AS; Levy AP; Ginsberg HN; Coca S; Lache O; Ransom T; Byington R; Rimm EB; Sapp J; Gardner M; Cahill LE
    J Am Coll Cardiol; 2020 Feb; 75(5):512-521. PubMed ID: 32029134
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The haptoglobin 2-2 genotype is associated with carotid atherosclerosis in 64-year old women with established diabetes.
    Ryndel M; Behre CJ; Brohall G; Prahl U; Schmidt C; Bergström G; Fagerberg B; Olson FJ
    Clin Chim Acta; 2010 Apr; 411(7-8):500-4. PubMed ID: 20064496
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Risk of Coronary Heart Disease Associated With Glycosylated Hemoglobin of 6.5% or Greater Is Pronounced in the Haptoglobin 2-2 Genotype.
    Cahill LE; Jensen MK; Chiuve SE; Shalom H; Pai JK; Flint AJ; Mukamal KJ; Rexrode KM; Levy AP; Rimm EB
    J Am Coll Cardiol; 2015 Oct; 66(16):1791-1799. PubMed ID: 26483103
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Relationship between angiotensin-converting enzyme gene insertion/deletion polymorphism, angiographically defined coronary artery disease and myocardial infarction in patients with type 2 diabetes mellitus.
    Narne P; Ponnaluri KC; Singh S; Siraj M; Ishaq M
    J Renin Angiotensin Aldosterone Syst; 2012 Dec; 13(4):478-86. PubMed ID: 22679279
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.